Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890721 | 0.87 | MAPK14 (0.77) | MAPK14PDE4AEGFRRAF1ADORA3 | |
| SCHEMBL6640633 | 0.83 | MAPK14 (1.00) | MAPK14PDE4AMAPK13MAPK12MAPK11 | |
| SCHEMBL2889128 | 0.81 | MAPK14 (0.72) | MAPK14PDE4AMAPK13MAPK12MAPK11 | |
| SCHEMBL6640304 | 0.80 | MAPK14 (1.00) | MAPK14PDE4A | |
| SCHEMBL6641727 | 0.78 | MAPK14 (0.71) | MAPK14PDE4AMAPK13MAPK12MAPK11 | |
| SCHEMBL6642816 | 0.78 | MAPK14 (0.72) | MAPK14PDE4AMAPK13MAPK12MAPK11 | |
| SCHEMBL27784867 | 0.77 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL25978284 | 0.77 | MAPK14 (0.66) | MAPK14PDE4AMAPK13MAPK12MAPK11 | |
| SCHEMBL6640155 | 0.76 | MAPK14 (0.74) | MAPK14PDE4AMAPK13MAPK12MAPK11 | |
| SCHEMBL6643926 | 0.75 | MAPK14 (0.60) | MAPK14PDE4AMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | claimed |
| EP-1025102-B1 | BICYCLIC KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2004-05-19 | — | — | EP | disclosed |
| US-6630485-B2 | For therapy of inflammatory disease | SYNTEX (U.S.A.) LLC | 2003-10-07 | — | — | US | disclosed |
| US-20030139462-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2003-07-24 | — | — | US | disclosed |
| US-6479507-B2 | MODULATION OF THESE INFLAMMATORY CYTOKINES IS CONSIDERED ONE OF THE MOST EFFECTIVE STRATEGIES TO BLOCK CHRONIC INFLAMMATION AND HAVE POSITIVE THERAPEUTIC OUTCOMES | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020013354-A1 | p38 map kinase inhibitors | CHENG SOAN (US) | 2002-01-31 | — | — | US | disclosed |
| US-20010044538-A1 | p38 MAP kinase inhibitors | CHENG SOAN (US) | 2001-11-22 | — | — | US | disclosed |
| US-6316464-B1 | P38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
| EP-1025102-A1 | BICYCLIC KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999020624-A1 | BICYCLIC KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 1999-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013354-A1 | p38 map kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885PDE4A 532/4885MAPK13 33/4885 |
| US-20030139462-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885PDE4A 532/4885MAPK13 33/4885 |
| US-20010044538-A1 | p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K1 | MAPK14 31/4885PDE4A 532/4885MAPK13 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.